Centrifuge Gene Therapy Purification & QC

Recombinant adeno-associated virus (rAAV) vectors are a highly promising mechanism for therapeutic gene delivery. However, most industrial cell lines exhibit inefficient gene pack[1]aging, which results in a heterogeneous population of vectors composed of empty, partial[1]ly-loaded, and fully-loaded capsids. Purifying, identifying and quantifying these different species is vital from a production and quality control standpoint. Improperly loaded viral capsids do not produce the desired therapeutic effect, but may still elicit an unintended im[1]mune response. This article and expert panel discussion will focus on a variety of pertinent topics in rAAV process development, with a focus on the benefits of analytical ultracentrif[1]ugation for vector purification and characterization. The article explores challenges of purification and QC within gene therapy with details on DGUC, Iodixanol vs CsCl for AAV, and characterizing AAV with AUC

Product Interest
Analytical Ultracentrifugation, Ultracentrifugation

Fill in the form below to download now.


    By checking the box below, please communicate whether you would like to receive communication, including promotional material from Beckman Coulter Life Sciences -

    If you have given your consent above, please confirm how you prefer us to contact you :

    Beckman Coulter Life Sciences Privacy Policy Global Privacy Notice - Beckman Coulter (mybeckman.in) and Terms of Use Online Terms of Use - Beckman Coulter (mybeckman.in)
    This is co-hosted by Express Pharma and Beckman Coulter both parties will process your personal information. Each party will be responsible for managing their own use of your personal information.
    By submitting this form, you are confirming you are an adult 18 years or older and you agree to Express Pharma contacting you with marketing-related emailer, messages, or by telephone. You may unsubscribe from receiving such communications from Express Pharma at any time. Express Pharma web sites and communications are subject to our Privacy Notice and Terms of Use.

    Comments (0)
    Add Comment